Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine with Cisplatin or Carboplatin in Advanced NSCLC
NCT00004201Phase 2Completed
- Sponsor
- Herbert Irving Comprehensive Cancer Center
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing Gemcitabine + Carboplatin with Gemcitabine + Cisplatin (2 arms). Primary endpoints: Objective Response Rate and Toxicity. Status: completed.
02
Drugs
carboplatincisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00004201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004201.